Matthew Hadfield, DO
Hematology & Oncology · Providence, RINPI 1811493414
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $9,247 of the $10,137 with a category attached, or 91.2%. F. Hoffmann-la Roche AG accounts for 92.8% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $9,727 and has fallen 96.1% since, to $383 in 2025.
Across 15 payments — averaging $675.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$9K
- Genentech, Inc.$247
- Merck$170
- Immunocore Limited$127
- Janssen Scientific Affairs, LLC$58
- Genentech USA, Inc.$46
- plus $80 from 3 others
Across 1 payment — averaging $16,987 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$17K
What the payments were for
- Travel & lodging$9,24791%
- Food & beverage$8909%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 3 | $9,407 |
| Genentech, Inc. | 2 | $247 |
| Merck | 3 | $170 |
| Immunocore Limited | 1 | $127 |
| Janssen Scientific Affairs, LLC | 2 | $58 |
| Genentech USA, Inc. | 1 | $46 |
| Daiichi Sankyo Inc. | 1 | $45 |
| Caris MPI, Inc. | 1 | $21 |
| Tempus AI, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,137 in reported general payments places this provider in the 80th percentile of 68 hematology & oncology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Providence
- William SikovProvidence$156K
- Ritesh RathoreProvidence$148K
- Anthony MegaProvidence$65K
- Adam OlszewskiProvidence$63K
- Hina KhanProvidence$34K
- Peter BarthProvidence$29K
- Thomas OllilaProvidence$19K
- John ReaganProvidence$18K
- Jennifer GassProvidence$16K
- Humera KhurshidProvidence$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.